MARKHAM, ON – (Marketwire – December 15, 2010) - Axxess Pharma Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in marketing and distribution of prescription and medical products sold without a prescription, is pleased to announce the acquisition of FORTEX rubbing Oil Actium Pharmaceuticals ®, Inc.. Acquisition now gives Axxess rapid input Pharma arthritis $ 35 billion market. FORTEX is currently sold in 20 countries around the world. Under the terms of the acquisition, Axxess Pharma now has exclusive rights to distribute in the Canada.
FORTEX is a topical medication requested by physicians on a daily basis. Drug provides relief fast and lasting pain associated with musculoskeletal disorders such as arthritis and soft tissue injuries. Once applied to the skin, FORTEX is readily absorbed directly to the pain site. Topical as FORTEX increased rapidly due to patient medications choose painful experience side effects caused by their oral pain medication. These side effects are well documented by health care professionals and patients and ranging from small, serious and sometimes fatal reactions.
Acting locally topical medications such as the FORTEX have the potential to have a safer side effects profile that they offer the drug directly to pain through the skin, which resulted in lower levels of the active ingredient into the bloodstream to oral medications. Axxess Pharma provides sales by Canadian market demand.
According to the Canada Arthritis Society, more than 4 million Canadians are diagnosed arthritis resulting in visits to the doctor to 8.8 million dollars per year for arthritis and related diseases. These figures are expected to continue to increase due to the aging population and obesity.
"I am satisfied with the Axxess Pharma and opportunities it brings to FORTEX Canadian market business relationship." FORTEX has a unique position in this market. The product works and allows clinicians and patients a cost-effective means of managing musculoskeletal pain and discomfort. "This is done to replace, reduce, or add to, therapy oral-NSAIDs, which is expensive and is accompanied by risk", said Michel Lockhart, representative for pharmaceuticals Actium.
For more information, please contact Investor relations at (973) 351-3868.
About Axxess Pharma, Inc..
Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the commercialization of the nutritionals dermatological, therapeutic management of pain and diagnostic products in the Canada and abroad since 1997. Axxess has 22 prepared prescription pharmaceutical products that are proven and overseas sales. The company has an experienced management team and field sales force on the market of products nationally for hospitals and pharmacies at retail, and specialized areas of practice including Dermatology and Nephrology, Neurology and Urology.
Safe Harbor
Statements about future expectations the company and all other statements in this news release, other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, 21st the section of the Securities Exchange Act of 1934, and that this term is defined in the Private Securities Litigation Reform Act of 1995. The company expects that such forward-looking statements be subject to established thus bypass.
Information above contains information relating to the company which is based on the beliefs of the company or its management, as well as assumptions made by the information currently available to the company or its management. When it is used in this document, the words "anticipate," "estimate," "expect," "intention", "plans", "plans" and similar expressions, as regards the management or the company are intended to identify forward-looking statements. Such statements reflect the current view of the company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties. If one or more of these risks or uncertainties materialize, or if underlying assumptions prove incorrect, actual results may vary materially those described herein as anticipated, raw, estimated, expected, intended or planned. In each case, the forward-looking information should consider in the light of the accompanying significant warnings below. Factors that could cause results to differ include, but are not limited performance success of internal plans, the impact of competitive services and prices and general economic risks and uncertainties.
No comments:
Post a Comment